Cohance Lifesciences (NSE:COHANCE) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:COHANCE Cohance Lifesciences Ltd NSE:COHANCE
82 GF Score
Price ₹455.95
GF Value ₹798.35
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Cohance Lifesciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cohance Lifesciences Valuation Rank Related Terms

NSE:COHANCE
82GF Score
Cohance Lifesciences Ltd NSE:COHANCE
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cohance Lifesciences (NSE:COHANCE) Overvalued in 2026?

Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued. The current stock price of ₹455.95 is trading 42.9% below its estimated GF Value™ of ₹798.35. GuruFocus considers Cohance Lifesciences to be Significantly Undervalued.

Key valuation signals for NSE:COHANCE:

  • Valuation Rank:
  • GF Value™: ₹798.35 vs. price of ₹455.95 (42.9% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the NSE:COHANCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cohance Lifesciences Business Description

Other Exchanges 543064:India
Address Hitech City Road, Panmaktha Plot, 1, 202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Knowledge City TSIIC Raidurg, Opposite IKEA, Hyderabad, TG, IND, 500081
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
82GF Score

Get the complete analysis for NSE:COHANCE

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹455.95
Price
₹798.35
GF Value